Adds further immunology expertise to Executive Management Team
Cambridge, UK – 10 November 2015 - Abzena plc (AIM:ABZA, ‘Abzena’), a life sciences group providing services and technologies that enable the development and manufacture of biopharmaceutical products, has appointed Dr Campbell Bunce to the new role of Senior Vice President, Scientific Operations.
Campbell will join Abzena’s Executive Management Team, reporting to John Burt, CEO. He will have responsibility for the immunology and protein engineering groups and will work alongside Chief Scientific Officer, Matthew Baker, to provide immunology expertise to support internal research and partners’ projects. Campbell will be based in Abzena’s Cambridge (UK) office.
Campbell joins from Oxford Immunotec where he was General Manager, Immunology Products, having previously worked at Immune Targeting Systems as R&D Director. He has a PhD in immunology from the University of Manchester.
Dr John Burt, CEO of Abzena commented:
“Campbell brings over 18 years’ valuable experience in immunology R&D and project management. We welcome him to the team as we continue to execute on our strategy of expanding our service and technology offering.”
Abzena provides proprietary technologies and complementary services in the UK and US to enable the development and manufacture of biopharmaceuticals.
The Group comprises Antitope, PolyTherics and PacificGMP, which between them have built a global customer base including the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
PacificGMP provides contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
Abzena (AIM: ABZA) has its main operations in Cambridge, UK and in San Diego, CA, USA. For more information, please see www.abzena.com.
Issued for and on behalf of Abzena by Instinctif Partners.
For more information please contact: email@example.com